NEW YORK (
CHANGE IN RATINGS
( ALM) initiated at Citi with a Buy rating and $15 price target. Several upcoming catalysts for the company's lead product, lluvien.
( ALM) initiated at Credit Suisse with an Outperform rating and $16 price target. Alimera's healthcare products can achieve high margins and rapid profitability.
rated new Hold at ThinkEquity. Valuation call, as earnings tailwinds could moderate in the coming quarters.
downgraded at Goldman from Neutral to Sell. $20 price target. Company is facing currency headwinds and is facing a year of strategic transition.
rated new Buy at ThinkEquity. Management has positioned the company well, with lower price points.
rated new Buy at Sterne Agee. $14 price target. Touch handset sales should drive growth.
upgraded at Morgan Joseph from Hold to Buy. Company seeing higher demand from domestic row farmers and in Brazil.
initiated at Barclays with an Overweight rating and $15 price target. The shopping center REIT is well positioned to take advantage of significant buying opportunities over next several years.
Great Atlantic & Pacific Tea
( GAP) initiated at Citi with a Hold rating and $6 price target. There could be significant upside if turnaround initiatives begin.
upgraded at Jefferies from Hold to Buy. Company has a strong pipeline and should benefit from currency volatility.
downgraded at Wells to Market Perform. Estimates raised, but the stock is already pricing in near-term growth.
upgraded at UBS from Neutral to Buy. $19 price target. Stock is down 30% over the past two months and appears attractively valued at less than 9 times earnings.
( JOYG) upgraded at Goldman from Neutral to Buy. $61 price target. Estimates also raised, as higher mining production should continue to boost CapEx rates.
upgraded at UBS from Neutral to Buy. $50 price target. Company has a solid footing and the potential to generate above-average earnings growth.
rated new Neutral at Susquehanna Financial. Stock is already pricing in the company's strong cash flow.
upgraded at Goldman to Buy. Stock was also added to the Conviction List, with a $65 price target. Stock is already discounting poor earnings results.
upgraded at Morgan Keegan from Market Perform to Outperform. Industrial and communications end-markets should benefit from an economic recovery.
rated new Positive at Susquehanna Financial. $36 price target. Company faces easy comparisons, and could be on the verge of a multi-year recovery.
downgraded at Goldman from Buy to Neutral. Valuation call, based on a $100 price target.
downgraded at Longbow from Buy to Neutral. $7.50 price target. Valuation call, as the stock is up 32% year-to-date.
initiated at Thomas Weisel with an Overweight rating and $17 price target. SPSC offers a SaaS-based electronic data integration service, primarily aimed at the consumer packaged goods segment.
downgraded at Goldman from Buy to Neutral. Stock was also removed from the Conviction Buy list, as the company faces several challenges with its new acquisition bid. $5 price target.
upgraded at Susquehanna from Neutral to Positive. $6.50 price target. Stock looks oversold, following news of a potential acquisition.
upgraded at Goldman from Sell to Neutral. $12.50 price target. Estimates also boosted, as the company has strong business momentum and will likely buyback more shares.
( WINN) initiated at Citi with a Buy rating and $16 price target. WINN's turnaround initiatives should drive productivity, which will lead to improved margins and EPS growth.
upgraded at Oppenheimer from Underperform to Perform. Commercial markets appear to be at or near a bottom.
STOCK COMMENTS / EPS CHANGES
target reduced at UBS to $68. Company has largely priced in risks of the Gulf spill. Buy rating.
estimates, target cut at Goldman. Shares of BBY now seen reaching $47. Estimates also reduced, given higher expected operating costs. Buy rating.
price target lower at Barclays to $55 from $60. COV's acquisition of ev3 gives it a franchise in the rapidly-growing neurovascular market. Maintain Overweight rating.
price target cut at Barclays to $11 from $22 as the company is under SEC investigation, delaying 1Q10 results. Maintain Equal Weight Rating.
target, estimates boosted at BofA/Merrill. FDO price target increased to $50 from $46 on continued broad-based sales strength and margin improvements. Estimates raised through 2012. Reiterate Buy rating.
estimates raised at Goldman through 2012. Air traffic demand and freight rates are improving. Neutral rating and $102 price target.
estimates cut at Morgan Stanley through 2012. Company had its rates frozen in Florida. Equal-weight rating and $42 price target.
estimates lowered at Morgan Stanley through 2012. Company likely to face a currency headwind in the coming quarters. Equal-weight rating.
This article was written by a staff member of TheStreet.com.